company background image

Instil Bio NasdaqGS:TIL Stock Report

Last Price


Market Cap







06 Oct, 2022


Company Financials +
TIL fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

TIL Stock Overview

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer.

Instil Bio Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Instil Bio
Historical stock prices
Current Share PriceUS$5.33
52 Week HighUS$23.22
52 Week LowUS$3.90
1 Month Change0.57%
3 Month Change-9.66%
1 Year Change-70.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO-79.84%

Recent News & Updates

Sep 06

Instil Bio appoints Tim Moore as COO

Instil Bio (NASDAQ:TIL) has appointed Tim Moore to the role of COO. Mr. Moore most recently served as the President and COO of PACT Pharma, a cell therapy company focusing on neo-antigen directed TCR-T cell therapy.

Jul 20
We're Keeping An Eye On Instil Bio's (NASDAQ:TIL) Cash Burn Rate

We're Keeping An Eye On Instil Bio's (NASDAQ:TIL) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

TILUS BiotechsUS Market

Return vs Industry: TIL underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: TIL underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is TIL's price volatile compared to industry and market?
TIL volatility
TIL Average Weekly Movement11.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: TIL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TIL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2018463Bronson Crouch

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others.

Instil Bio Fundamentals Summary

How do Instil Bio's earnings and revenue compare to its market cap?
TIL fundamental statistics
Market CapUS$691.27m
Earnings (TTM)-US$211.46m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TIL income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$211.46m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.63
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio10.7%

How did TIL perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is TIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TIL?

Other financial metrics that can be useful for relative valuation.

TIL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-1.9x
PEG Ration/a

Price to Book Ratio vs Peers

How does TIL's PB Ratio compare to its peers?

TIL PB Ratio vs Peers
The above table shows the PB ratio for TIL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.8x
YMAB Y-mAbs Therapeutics
ALT Altimmune
NKTX Nkarta
CRBU Caribou Biosciences
TIL Instil Bio

Price-To-Book vs Peers: TIL is good value based on its Price-To-Book Ratio (1.5x) compared to the peer average (2.8x).

Price to Earnings Ratio vs Industry

How does TIL's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: TIL is good value based on its Price-To-Book Ratio (1.5x) compared to the US Biotechs industry average (1.7x)

Price to Book Ratio vs Fair Ratio

What is TIL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TIL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TIL's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of TIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TIL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TIL's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is Instil Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TIL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TIL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TIL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TIL's revenue (95% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: TIL's revenue (95% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: TIL is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Instil Bio performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Last years earnings growth

Earnings and Revenue History

Quality Earnings: TIL is currently unprofitable.

Growing Profit Margin: TIL is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TIL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TIL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: TIL has a negative Return on Equity (-46.14%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Instil Bio's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: TIL's short term assets ($367.7M) exceed its short term liabilities ($43.2M).

Long Term Liabilities: TIL's short term assets ($367.7M) exceed its long term liabilities ($67.0M).

Debt to Equity History and Analysis

Debt Level: TIL has more cash than its total debt.

Reducing Debt: Insufficient data to determine if TIL's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TIL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TIL has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 69.8% each year.

Discover healthy companies


What is Instil Bio current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Instil Bio Dividend Yield vs Market
How does Instil Bio dividend yield compare to the market?
SegmentDividend Yield
Company (Instil Bio)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Instil Bio)n/a

Notable Dividend: Unable to evaluate TIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TIL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TIL has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Bronson Crouch (49 yo)





Mr. Bronson Crouch is the Chief Executive Officer and Chairman at Instil Bio, Inc. since November 2018. Mr. Crouch has served as Founding Partner of Curative Ventures Management LLC since January 2014. Mr....

CEO Compensation Analysis

Bronson Crouch's Compensation vs Instil Bio Earnings
How has Bronson Crouch's remuneration changed compared to Instil Bio's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$36mUS$618k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$6mUS$438k


Compensation vs Market: Bronson's total compensation ($USD35.78M) is above average for companies of similar size in the US market ($USD3.98M).

Compensation vs Earnings: Bronson's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: TIL's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Experienced Board: TIL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TIL?
Owner TypeNumber of SharesOwnership Percentage
General Public2,666,1852.1%
Individual Insiders3,161,9992.4%
VC/PE Firms58,137,65344.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 93.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Curative Ventures
Vivo Capital, LLC
CPMG, Inc.
RA Capital Management, L.P.
VR Adviser, LLC
BlackRock, Inc.
4,200,033$22.4m24.96%no data
The Vanguard Group, Inc.
4,189,689$22.3m0.89%no data
Baker Bros. Advisors LP
Bearing Circle Capital LLC
ArrowMark Colorado Holdings, LLC
Bronson Crouch
2,399,999$12.8m0%no data
Samsara BioCapital LLC
Marshall Wace LLP
State Street Global Advisors, Inc.
925,526$4.9m8.22%no data
Geode Capital Management, LLC
802,167$4.3m19.16%no data
George Matcham
762,000$4.1m0%no data
Fairmount Funds Management LLC
Medical Strategy GmbH, Asset Management Arm
Northern Trust Global Investments
488,061$2.6m22.52%no data
Artal Group S.A.
Nicholas Investment Partners, L.P.
Logos Global Management, L.P.
Renaissance Technologies LLC
355,035$1.9m0%no data
Citadel Advisors LLC
350,148$1.9m58.41%no data

Company Information

Instil Bio, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Instil Bio, Inc.
  • Ticker: TIL
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$691.271m
  • Shares outstanding: 129.69m
  • Website:

Number of Employees


  • Instil Bio, Inc.
  • 3963 Maple Avenue
  • Suite 350
  • Dallas
  • Texas
  • 75219
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TILNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.